Abstract
Darolutamide (Daro) and enzalutamide (Enza) are next generation androgen receptor inhibitors. Daro does not significantly penetrate the blood-brain barrier, which may reduce cognitive impairment. ODENZA is a prospective, cross-over, preference, randomized phase II trial of Daro and Enza in patients (pts) with mCRPC. Pts (n=249) were randomized 1/1 to receive Daro 1200 mg/d for 12 weeks followed by Enza 160 mg/d for 12 weeks or the reverse sequence. Numerically more pts with early mCRPC preferred Daro over Enza, although the difference did not reach significance (Colomba et al, ASCO 2021).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
